A new blood test can provide a more detailed picture of how far the disease has progressed in a person with Alzheimer's. By measuring protein fragments in the blood, researchers can now assess the extent of tau tangles in the brain - a key characteristic of the disease. This is shown by a major international study led by researchers at Lund University and Banner Health.
In a study published in JAMA, researchers present a newly developed blood test that can identify advanced tau changes with a high degree of accuracy.
Unlike the blood-based biomarker p-tau217 - the biomarker most widely used in Alzheimer's research and clinical care, and which Lund University has previously reported on - the biomarker used by the researchers identifies clearer distinctions between early and late stages of the disease.
A simple test that can be used on a very large scale to determine the extent of tau tangle accumulation in the brain is a major step forward in our understanding of Alzheimer's disease.
Test enables quantification of tau changes
One of the biggest challenges in diagnosing cognitive impairment is determining whether the patient's problems are caused specifically by Alzheimer's-related changes or are due to other causes.
"This is a significant breakthrough in Alzheimer's research. A simple blood test enables an assessment of how widespread tau tangles are in the brain, and to do so on a large scale. In my role as a doctor, I look forward to the prospect of being able, in the future, to identify and quantify tau changes in my patients using a single blood test. This is precisely what is missing when it comes to determining, in an easily accessible way, whether a patient's symptoms are likely to be caused by Alzheimer's-related changes," says Niklas Mattson-Carlgren.
Niklas Mattson-Carlgren, one of the researchers behind the study, is a professor at Lund University and a specialist in neurology at the Memory Clinic, Skåne University Hospital,
Although p-tau217 rises early in the course of the disease and indicates the accumulation of amyloid plaques, the marker provides limited information about the accumulation of tau tangles in the later stages of the disease. The new test targets a different biological marker, the protein eMTBR-tau, which more directly reflects the amount of tau tangles that have accumulated in the brain. The study's findings suggest that the two markers, when used together, can provide a more complete picture of how the disease progresses.
As protein fragments can be measured in the blood (in the same way as p-tau217), the test could, in the long term, become a considerably simpler alternative to the invasive and expensive tests and specialised brain imaging currently required.
A step towards a simpler, less expensive test
To date, measuring eMTBR-tau has required specialised methods that are difficult to use except in highly advanced laboratories. The new blood test requires only a very small amount of blood and is based on what is known as an immunoassay - an antibody-based test that is suitable for large-scale use. This is a significant step towards making the test available to far more researchers and clinics, and towards monitoring the progression of the disease in the body during clinical trials. In the long term, the researchers hope that the method for measuring eMTBR-tau can be introduced into routine clinical practice.
"A simple test that can be used on a very large scale to determine the extent of tau tangle accumulation in the brain is a major step forward in our understanding of Alzheimer's disease," says Nicholas Ashton, the study's corresponding author and head of Banner's Fluid Biomarker Program at the Banner Sun Health Research Institute. He is also a researcher at the Sahlgrenska Academy, University of Gothenburg.
While p-tau217 detects early signs of Alzheimer's disease, eMTBR-tau measures the amount of tau tangles present in the brain. Together, these two markers could help doctors make the correct diagnosis, take better treatment decisions and identify the right patients for clinical trials.
In the study, the results of the blood test closely matched those obtained using advanced methods involving mass spectrometry, which confirmed the test's accuracy. Both the blood test and the established advanced methods identified advanced tau changes with the same high degree of accuracy. Furthermore, post-mortem analysis of brain tissue confirmed that eMTBR-tau can be used to estimate the total accumulation of tau tangles.
Further studies are now required before the method can be made available for clinical use.
"We are now looking forward to continuing our research into eMTBR-tau and validating it for use in routine clinical practice," says Niklas Mattsson-Carlgren.